rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Charming Medical Limited - Class A

MCTA · Nasdaq

Health CareProviders & FacilitiesNot moving yet

MCTA stood above a rising 150-day average in 0 of the last 18 weekly readings. It is 0.0% above that average now. Providers & Facilities: 51% of its 53 stocks in an uptrend (+8 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 18
Industry in uptrend
51% +8 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
2 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 18 weeks.

23 Apr – 22 Oct
28%44%59%Apr 26Jun 26Jul 26Sep 26Oct 26

Providers & Facilities: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders2+0 on the quarter
New · exited0 · 0
Reported value$1.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
UBS Group AGreduced · filed 13 Aug 202624,249$712K-700−2.8%
GEODE CAPITAL MANAGEMENT, LLCunchanged · filed 12 Aug 202610,752$316K00.0%
31 Dec 2025 – 30 Jun 2026
123Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Nobody on record has traded it.

Same industry

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 31 Mar 202699.3%
Operating profit marginFY 2026 · to 31 Mar 2026-0.6%
Free cash flow marginFY 2026 · to 31 Mar 2026-32.4%
Return on capital employedFY 2026 · to 31 Mar 2026-0.5%
Cash conversionFY 2026 · to 31 Mar 202535.5%
Debt to equityFY 2026 · to 31 Mar 20260.07×
Interest coverFY 2026 · to 31 Mar 2026-1.85×
Revenue growthFY 2026 · to 31 Mar 20253.4%
Earnings per share growthFY 2026 · to 31 Mar 202560.0%
Share count trendFY 2026 · to 31 Mar 20250.0%
Cash and equivalentsFY 2026 · to 31 Mar 2026$4.7M
Free cash flowFY 2026 · to 31 Mar 2026−$1.6M

Analyst forecasts

No analyst forecasts yet.